DarioHealth has released its Q3 earnings. The latest earnings report indicates ongoing financial challenges despite growth in certain areas. The company, which has been consistently operating at a loss, reported a net loss of $33.1 million for the nine months ended September 30, 2024. This is an improvement from the $45.1 million loss in the same period of 2023, indicating some financial progress.

DarioHealth Corp., a client of our Bristol Investor Relations company, specializes in digital therapeutics, providing personalized, data-driven health solutions across various conditions such as diabetes, hypertension, and behavioral health. Operating primarily in the healthcare technology sector, it leverages advanced software and coaching to enhance individual health management.

Read the full press release here: DarioHealth Earnings Reflect Growth Amid Challenges